OakChart

Kazia Therapeutics Limited ADR

KZIAHealthcare·Biotechnology·Australia·Micro·NASD·Nov 11 • 10:13 AM ET

7.53+0.13 (1.82%)
2026-11-11 16:13 CET
Market cap
84.56 USD m
Revenue, TTM
0.03 USD m
Net income, TTM
-14.73 USD m
Free cash flow, TTM
- USD m
EPS diluted, TTM
-6.82
P/E
-
Compare

Price

KZIA against its 20, 50 and 200-day averages
2050200earnings
7.5010.0012.5015.0017.50590K1.2MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26KZIAclose 7.5420-day 7.8450-day 9.21200-day 10.567.54

56.7% under 17.40 on 8 Dec 2025. Last 15 sessions, 32.1% high to low

Profile

KZIA
52-week range, 21% of the way up
4.8617.40

Kazia Therapeutics Ltd. is an oncology-focused biotechnology company, which engages in the business of pharmaceutical drug development. It focuses on its Paxalisib program, which is designed to treat brain cancer. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.

IPOJan 06, 1999
Beta2.37
ATR, 14d0.66
Rel volume0.20
Short float14.70%
Insider own14.01%
Inst own41.96%

Snapshot

6 groups

Valuation

Index-
Market Cap86.13M
Enterprise Value39.88M
Income-14.73M
Sales0.03M
Book/sh2.73
Cash/sh4.05
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees-
IPOJan 06, 1999

Ratios

P/E-
Forward P/E-
PEG-
P/S2870.83
P/B2.76
P/C1.86
P/FCF-
EV/EBITDA-
EV/Sales1329.17
Quick Ratio2.87
Current Ratio2.87
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)-6.82
EPS next Y-1.41
EPS next Q-0.07
EPS this Y23.28%
EPS next Y-56.27%
EPS next 5Y-10.25%
EPS past 3/5Y43.68% 25.92%
Sales past 3/5Y- -
EPS Y/Y TTM76.83%
Sales Y/Y TTM-98.25%
EPS Q/Q67.55%
Sales Q/Q-
EarningsSep 04
EPS/Sales Surpr.0.00% 0.00%

Ownership

Insider Own14.01%
Insider Trans0.00%
Inst Own41.96%
Inst Trans16.65%
ROA-50.34%
ROE-102.88%
ROIC-47.53%
Gross Margin-
Oper. Margin-49070.50%
Profit Margin-55271.07%
SMA20-3.85%
SMA50-18.16%
SMA200-28.64%
Trades-

Technical

Shs Outstand11.34M
Shs Float9.83M
Short Float14.70%
Short Ratio5.49
Short Interest1.45M
52W High17.40 -56.70%
52W Low4.86 55.04%
Volatility9.59% 9.64%
ATR (14)0.66
RSI (14)40.57
Beta2.37
Rel Volume0.20
Avg Volume263.40K
Volume8,081

Performance

Perf Week-6.75%
Perf Month-6.28%
Perf Quarter-42.96%
Perf Half Y-46.18%
Perf YTD9.36%
Perf Year-1.63%
Perf 3Y-76.45%
Perf 5Y-98.68%
Perf 10Y-97.63%
Recom1.00
Target Price31.14
Prev Close7.40
Price7.53
Change %1.82%

Analyst ratings

latest 10 of 10
DateActionAnalystRating changeTargetImplied
Oct 30, 2026InitiatedNNeedhamBuy$27+258.3%
Oct 21, 2026InitiatedGGuggenheimBuy$35+364.5%
Oct 20, 2026InitiatedLLeerink PartnersOutperform$30+298.1%
Aug 13, 2026InitiatedCCanaccord GenuityBuy$29+284.9%
Jul 01, 2026InitiatedBBTIG ResearchBuy$34+351.2%
Jun 11, 2026InitiatedLLake StreetBuy$32+324.7%
Apr 15, 2026InitiatedLLaidlawBuy$25+231.8%
Feb 06, 2025InitiatedMMaxim GroupBuy$3-60.2%
Oct 14, 2021InitiatedMMaxim GroupBuy$18+138.9%
Jan 05, 2021InitiatedHH.C. WainwrightBuy$17+125.6%

Peers

Mkt cap
TickerCompanyMkt cap
NTHINeOnc Technologies Holdings Inc129.25M
MBRXMoleculin Biotech Inc8.90M
CRDFCardiff Oncology Inc60.03M
ONCYOncolytics Biotech Inc49.41M
BOLDBoundless Bio Inc54.82M
IMMPImmutep Limited ADR26.37M
ACTUActuate Therapeutics Inc17.53M
ATHEAlterity Therapeutics Ltd ADR45.07M
SLXNSilexion Therapeutics Corp1.78M
DRTSAlpha Tau Medical Ltd1.32B

Held by

AUM
TickerCompanyAUM
APIEActivePassive International Equity ETFAUM: 1.13B

News

latest 14 of 204
  • Kazia Therapeutics Recognized as "Drug Discovery Company of the Year" in 2026 BioTech Breakthrough Awards (PR Newswire) -13.37%
  • Kazia Therapeutics Announces Two Abstracts on Paxalisib Tumor and Immune Reprogramming Research Accepted for Poster Presentation at 2026 San Antonio Breast Cancer Symposium (PR Newswire) -5.65%
  • Kazia Therapeutics to Participate in Fireside Chat at Guggenheim 3rd Annual Healthcare Innovation Conference (PR Newswire)
  • Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders (PR Newswire)
  • Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer (PR Newswire)
  • Loading…
  • Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy (PR Newswire) -8.28%
  • Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer (PR Newswire)
  • Kazia closes oversubscribed offering to fund paxalisibs clinical development (Pharmaceutical Technology)
  • Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering (PR Newswire)
  • Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering (PR Newswire) -19.64%
  • Kazia Therapeutics Limited Announces Proposed Public Offering (PR Newswire) +15.75%
  • Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer (PR Newswire)
  • Kazia Therapeutics Appoints James Levine as Chief Financial Officer (PR Newswire) -6.13%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026S22026-09-04-0.606-0.606-0.5650.490.494
2026S12026-03-03-0.388-0.007-0.5790.180.001
2025S22025-08-28-0.433-0.007-4.1840.010.011
2024S22024-08-29-15.000-15.000-21.3110.100.101
2023S12023-02-28-31.448--31.2430.00--
2022S22022-10-01-29.930--31.4170.00-2
2022S12022-02-23-35.715--36.0800.020.00-
2021S22021-10-13-7.370--6.01311.20--
2021S12021-02-24-23.455-2.305-21.4090.000.46-
2027S1---0.068--1.993
2027S2---0.077--1.053

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-59.155-35.680-54.8200.722.78
2021FY-25.940--26.68511.00-
2022FY-64.080-65.105-68.4780.020.01
2023FY-36.253-35.311-37.3520.020.00
2024FY-30.000-30.000-33.2800.100.10
2025FY-1.233-0.013-2.4520.040.04
2026FY-1.055-1.330-1.1750.590.48
2027FY--0.902--1.05
2028FY--1.409--1.13
2029FY--1.575--1.17
2030FY--2.477--13.05
2031FY--1.549--39.63

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2027S1S2026-10-292001.991.962.02
2027S1S2026-10-191001.961.961.96
2027S1R2026-09-04100-0.45-0.45-0.45
2027S1R2026-06-03100-0.45-0.45-0.45
2027S1E2026-10-29300-0.07-0.200.00
2027S1E2026-10-20200-0.10-0.200.00
2027S1E2026-10-191000.000.000.00
2027S1E2026-09-04100-0.45-0.45-0.45
2027S1E2026-06-03100-0.45-0.45-0.45
2027FYS2026-10-296201.050.002.11
2027FYS2026-10-205200.860.002.11
2027FYS2026-09-094200.580.002.11
2027FYS2026-09-044200.570.002.09
2027FYS2026-09-014200.570.002.09

Estimate history

EPS, annual-82.387-46.332-61.217-54.82-26.685-68.478-37.352-33.28-12.234
Period201720182019202020212022202320242025
EPS, quarterly
Period
Sales, annual000011.322001.5130.027
Period201720182019202020212022202320242025
Sales, quarterly
Period
Shares, annual0.1010.1010.130.1970.2640.2780.4560.6661.619
Period201720182019202020212022202320242025
Shares, quarterly
Period

Income statement, annual

Currency USD, millions
MetricTTM2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.03-1.510.000.0011.320.000.000.00
Cost of Goods Sold Incl. D&A---1.261.36-0.730.781.20
Gross Profit----1.26-1.36--0.73-0.78-1.20
Selling, General and Administrative Excl. Other13.10-19.0514.9917.0614.828.116.5510.60
Research and Development5.20-10.179.2113.2710.846.364.637.57
Other Operating Expense0.00-0.000.000.000.000.00-0.000.00
Operating Income-13.07--18.77-16.24-18.42-4.44-8.84-7.33-11.80
Interest Expense----0.000.000.000.000.00
Unusual Expense3.99--0.92-2.280.001.920.431.34-4.48
Net Income Before Taxes-15.75--17.84-13.95-18.41-6.64-9.21-8.58-6.62
Income Taxes-1.02--0.29-0.18-0.27-0.36-0.85-1.24-1.94
Consolidated Net Income-14.73--17.55-13.77-18.14-6.28-8.36-7.35-4.68
Net Income From Continuing Operations-14.73--17.55-13.77-18.14-6.28-8.36-7.35-4.68
Net Income-14.73--17.55-13.77-18.14-6.28-8.36-7.35-4.68
EPS (Recurring)-3.83--34.50-41.68-68.48-20.98-52.84-53.41-77.42
EPS (Basic, Before Extraordinaries)-6.82--33.28-37.35-68.48-26.68-54.82-61.22-46.33
EPS (Diluted)-6.82--33.28-37.35-68.48-26.68-54.82-61.22-46.33
EBITDA-13.10--17.54-14.99-17.06-3.49-8.11-6.55-10.60
Non-Operating Income (Expense)1.31-0.010.020.01-0.290.060.080.70
Other After Tax Adjustments0.00-0.000.000.000.000.000.000.00
Stock Option Compensation Expense3.20-0.240.550.850.330.120.120.09
Price To Sales Ratio806.93-3.98--10.25---
Operating Margin-49,070.50--1,240.68---39.19---
Net Margin-55,271.07--1,160.22---55.47---
Shares Outstanding11.34-0.670.460.280.260.200.130.10
Market Capitalization84.56-270.151,322.572,913.866,534.811,603.44809.72716.46

Income statement, quarterly

Currency USD, millions
Metric2026S12025S22025S12024S22024S12023S22023S12022S2
Total Revenue0.000.030.001.520.000.000.000.00
Cost of Goods Sold Incl. D&A0.00-0.00-0.610.630.630.70
Gross Profit0.00-0.00--0.61-0.63-0.63-0.70
Selling, General and Administrative Excl. Other8.884.225.5913.905.196.478.517.64
Research and Development3.271.932.217.982.213.565.645.93
Other Operating Expense0.000.000.620.000.000.000.000.00
Operating Income-8.88-4.20-6.21-13.00-5.80-7.10-9.14-8.34
Interest Expense-------0.00
Unusual Expense-0.494.470.83-0.980.05-2.350.060.06
Net Income Before Taxes-8.23-7.52-7.00-11.91-5.85-4.74-9.19-8.39
Income Taxes0.00-1.02-0.09-0.09-0.09-0.09-0.09-0.04
Consolidated Net Income-8.23-6.50-6.91-11.82-5.76-4.65-9.10-8.36
Net Income From Continuing Operations-8.23-6.50-6.91-11.82-5.76-4.65-9.10-8.36
Net Income-8.23-6.50-6.91-11.82-5.76-4.65-9.10-8.36
EPS (Recurring)-2.75-2.17-7.45-22.54-11.93-13.79-31.11-31.27
EPS (Basic, Before Extraordinaries)-2.64-4.18-8.13-21.31-12.01-10.19-31.24-31.42
EPS (Diluted)-2.64-4.18-8.13-21.31-12.01-10.19-31.24-31.42
EBITDA-8.88-4.22-5.59-12.38-5.19-6.47-8.51-7.64
Non-Operating Income (Expense)0.171.150.030.120.000.020.000.00
Stock Option Compensation Expense3.040.160.130.040.200.100.440.52
Price To Sales Ratio806.93365.594.954.17----
Operating Margin--15,745.94--855.79----
Net Margin--24,400.33--777.92----
Shares Outstanding11.341.620.970.670.530.460.330.28
Market Capitalization84.566.0629.46270.15519.381,322.57502.402,913.86

Balance sheet, annual

Currency USD, millions
Metric2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments-1.113.495.0620.716.033.814.4011.09
Short Term Receivables-2.602.600.060.060.821.091.713.11
Inventories-0.000.000.000.000.000.000.000.00
Other Current Assets-0.391.091.371.290.480.370.730.74
Total Current Assets-4.107.176.5022.077.345.276.8414.94
Net Property, Plant & Equipment-0.000.000.000.000.000.000.000.38
Total Investments and Advances-0.000.000.000.000.000.123.200.02
Long-Term Note Receivable-0.030.035.025.03----
Intangible Assets-10.2811.5013.1616.528.549.4710.7712.21
Other Assets-0.000.000.000.000.000.000.000.00
Total Assets-14.4218.6924.6843.6115.8814.8620.8227.54
Short Term Debt Incl. Current Port. of LT Debt-0.421.201.270.000.000.000.000.00
Accounts Payable-3.040.571.051.421.170.741.040.96
Income Tax Payable-----0.210.210.23-
Other Current Liabilities-13.773.272.314.832.320.601.833.17
Total Current Liabilities-17.235.044.636.253.691.543.104.13
Long Term Debt-0.000.000.000.000.000.000.000.46
Provision for Risks Charges-0.020.040.080.040.000.000.000.05
Deferred Tax Liabilities-1.351.521.762.202.142.392.743.31
Other Liabilities-2.514.075.646.700.320.960.770.62
Total Liabilities-21.1110.6712.1115.196.154.906.608.57
Non-Equity Reserves-0.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value-0.000.000.000.000.000.000.000.00
Common Equity--6.698.0212.5728.429.739.9614.2218.98
Total Shareholders Equity--6.698.0212.5728.429.739.9614.2218.98
Accumulated Minority Interest-0.000.000.000.000.000.000.000.00
Total Equity--6.698.0212.5728.429.739.9614.2218.98
Total Liabilities & Stockholders Equity-14.4218.6924.6843.6115.8814.8620.8227.54
Book Value Per Share--10.0517.5945.28107.6349.2676.78140.72188.13
Tangible Book Value Per Share--25.50-7.62-2.1445.065.983.7934.1067.07
Price to Book Ratio-8.3816.4922.7322.9017.206.543.714.78
Return on Assets--106.01-64.43-53.13-21.11-54.38-41.18-19.35-29.81
Return on Equity--2,635.88-132.13-88.54-32.93-84.91-60.77-28.19-37.46
Return on Invested Capital---171.63-144.37-22.10-85.94-73.75-32.91-41.40
Quick Ratio-0.241.421.403.531.993.422.213.62
Current Ratio-0.241.421.403.531.993.422.213.62

Cash flow, annual

Currency USD, millions
MetricTTM2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-14.45--17.55-13.77-18.14-6.28-8.36-7.35-4.68
Depreciation-0.03-1.221.261.360.940.730.781.20
Other Funds (Non Cash)7.01-3.49-0.60-0.352.710.611.52-4.42
Funds from Operations-7.46--12.83-13.11-17.13-2.99-7.22-5.27-8.14
Extraordinary Item--0.000.000.000.000.000.000.00
Changes in Working Capital-1.30-7.322.94-0.71-3.811.320.471.43
Income Taxes Payable---0.18-0.18-0.27----
Cash from Operating Activities-8.76--5.52-10.17-17.84-6.79-5.91-4.80-6.71
Capital Expenditures--0.000.000.000.000.000.000.00
Net Assets From Acquisitions--0.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses--0.000.000.000.000.000.000.00
Purchase or Sale of Investments--0.000.000.000.000.001.690.00
Purchase of Investments--0.000.000.000.000.000.00-
Sale Or Maturity of Investments--0.000.000.000.000.001.690.00
Other Uses--0.000.00-1.720.000.000.000.00
Other Sources--0.000.000.000.000.000.000.12
Cash from Investing Activities--0.000.00-1.720.000.001.690.12
Cash Dividends Paid--0.000.000.000.000.000.000.00
Change in Capital Stock39.69-3.668.732.7020.968.142.730.00
Repurchase of Common Pref Stock--0.000.000.000.000.000.000.00
Sale of Common Pref Stock39.69-3.668.732.7020.968.142.730.00
Proceedsfrom Stock Options39.69-3.668.732.7020.968.142.730.00
Issuance or Reduction of Debt, Net-0.35--0.50-0.031.340.000.000.000.00
Change in Long Term Debt--0.000.000.000.000.000.000.00
Issuance of Long Term Debt--0.000.000.000.000.000.000.00
Reduction of Long Term Debt--0.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow13.37-0.000.000.000.000.000.000.00
Other Financing Activities Uses--0.000.000.000.000.000.000.00
Cash from Financing Activities52.71-3.168.704.0420.968.142.730.00
Exchange Rate Effect-0.50-0.010.040.85-0.130.000.010.01
Net Change in Cash43.44--2.35-1.43-14.6714.042.23-0.37-6.58
Free Cash Flow---5.52-10.17-17.84-6.79-5.91--6.71
Preferred Dividends (Cash Flow)--0.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit--0.000.000.00-0.36-0.20-0.21-0.24

Balance sheet, quarterly

Currency USD, millions
Metric2026S12025S22025S12024S22024S12023S2
Cash & Short Term Investments46.322.851.901.112.433.49
Short Term Receivables0.210.060.062.602.552.60
Inventories0.000.00-0.000.000.00
Other Current Assets0.140.320.150.390.481.09
Total Current Assets46.673.232.114.105.467.17
Net Property, Plant & Equipment0.000.00-0.000.000.00
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.720.718.9610.2811.1511.50
Other Assets0.000.000.000.000.000.00
Total Assets47.423.9711.0914.4216.6418.69
Short Term Debt Incl. Current Port. of LT Debt0.070.260.090.420.251.20
Accounts Payable4.093.703.923.040.710.57
Other Current Liabilities12.105.256.2213.776.783.27
Total Current Liabilities16.259.2110.2217.237.745.04
Long Term Debt0.000.00-0.000.000.00
Deferred Tax Liabilities0.180.181.171.351.471.52
Other Liabilities0.000.002.042.513.794.07
Total Liabilities16.439.4113.4521.1113.0410.67
Non-Equity Reserves0.000.00-0.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity30.99-5.44-2.36-6.693.598.02
Total Shareholders Equity30.99-5.44-2.36-6.693.598.02
Accumulated Minority Interest0.000.00-0.000.000.00
Total Equity30.99-5.44-2.36-6.693.598.02
Total Liabilities & Stockholders Equity47.423.9711.0914.4216.6418.69
Book Value Per Share2.73-3.36-2.44-10.056.8217.59
Tangible Book Value Per Share2.67-3.80-11.70-25.50-14.32-7.62
Price to Book Ratio2.71-2.57-4.408.386.2516.49
Return on Assets-50.34-145.87-135.08-106.16-58.60-64.35
Return on Equity-102.88--3,028.18-2,639.76-181.77-131.96
Return on Invested Capital-26.54----160.22-57.94
Quick Ratio2.870.35-0.240.711.42
Current Ratio2.870.350.210.240.711.42

Cash flow, quarterly

Currency USD, millions
Metric2026S12025S22025S12024S22024S12023S2
Net Income-8.23-6.22-6.91-11.87-5.76-4.72
Depreciation0.00-0.030.620.620.610.64
Other Funds (Non Cash)2.424.591.443.030.47-1.54
Funds from Operations-5.80-1.66-4.85-8.21-4.67-5.53
Extraordinary Item0.00--0.000.000.00
Changes in Working Capital-0.25-1.05-0.716.810.541.23
Cash from Operating Activities-6.06-2.71-5.57-1.41-4.13-4.31
Capital Expenditures0.00--0.000.000.00
Net Assets From Acquisitions0.00--0.000.000.00
Sale of Fixed Assets and Businesses0.00--0.000.000.00
Purchase or Sale of Investments0.00--0.000.000.00
Purchase of Investments0.00--0.000.000.00
Sale Or Maturity of Investments0.00--0.000.000.00
Other Uses0.00--0.000.000.00
Other Sources0.00--0.000.000.00
Cash from Investing Activities0.00--0.000.000.00
Cash Dividends Paid0.00--0.000.000.00
Preferred Dividends (Cash Flow)0.00--0.000.000.00
Change in Capital Stock35.214.485.662.810.874.84
Repurchase of Common Pref Stock0.00--0.000.000.00
Sale of Common Pref Stock35.214.485.662.810.874.84
Proceedsfrom Stock Options35.214.485.662.810.874.84
Issuance or Reduction of Debt, Net-0.19-0.150.00-0.760.26-0.03
Change in Long Term Debt0.00--0.000.000.00
Issuance of Long Term Debt0.00--0.000.000.00
Reduction of Long Term Debt0.00--0.000.000.00
Net Financing Active Other Cash Flow14.14-0.780.78-1.971.970.00
Other Financing Activities Uses0.00--0.000.000.00
Cash from Financing Activities49.163.556.440.073.104.81
Exchange Rate Effect-0.44-0.070.060.07-0.060.05
Net Change in Cash42.670.780.93-1.26-1.100.56
Free Cash Flow-6.06---1.41-4.13-4.31

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3014.70%1.4M9.8M271.57K
2026-10-1513.31%1.3M9.8M273.08K
2026-09-3011.94%1.2M9.8M264.12K
2026-09-157.83%0.8M9.8M238.40K
2026-08-319.21%0.9M9.8M213.82K
2026-08-145.69%0.6M9.8M197.22K
2026-07-316.91%0.7M9.8M194.22K
2026-07-157.59%0.7M9.8M219.22K
2026-06-306.63%0.6M9.8M228.87K
2026-06-156.47%0.6M9.8M217.70K
2026-05-295.47%0.5M9.8M209.15K
2026-05-153.72%0.4M9.8M214.07K
2026-04-304.19%0.4M9.8M204.91K
2026-04-151.91%0.2M9.8M191.30K
2026-03-315.86%0.1M1.6M202.54K
2026-03-132.78%0.0M1.6M224.13K
2026-02-274.21%0.1M1.6M240.64K
2026-02-133.01%0.0M1.6M797.42K
2026-01-301.93%0.0M1.6M780.34K
2026-01-155.35%0.1M1.6M743.84K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.502.507.400.0034.1060.000.000.978-0.0140.001
call5.000.505.003.7010.24820.000.000.948-0.0130.001
call7.500.055.003.0012.1721410.000.834-0.2000.003
call10.000.005.000.0513.32389.000.000.820-0.2280.003
call12.500.004.000.0513.8131,0230.000.807-0.2520.003
call15.000.005.000.2914.75891.000.000.808-0.2640.003
call17.500.005.000.2515.2586.000.000.804-0.2760.003
call20.000.005.000.1215.91455.000.000.806-0.2820.003
call22.500.005.000.0016.2700.000.000.803-0.2910.003
call25.000.055.000.1016.58046.000.000.801-0.2980.003
put2.500.005.000.004.0840.000.00-0.022-0.0140.001
put5.000.000.050.052.19265.000.00-0.101-0.0240.002
put7.500.351.201.2012.29933.005.00-0.166-0.1990.003
put10.000.605.002.307.0875.000.00-0.185-0.2300.003
put12.502.707.504.797.85516.000.00-0.182-0.2440.003
put15.005.2010.000.008.6720.000.00-0.192-0.2620.003
put17.507.8012.500.009.1420.000.00-0.191-0.2700.003
put20.0010.2015.0013.009.6120.000.00-0.194-0.2800.003
put22.5012.7017.500.0010.1130.000.00-0.202-0.2930.003
put25.0015.2020.000.0010.4600.000.00-0.205-0.3000.003

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-02NT 20-F2026-06-30SEC
2026-10-02SCHEDULE 13G/ASEC
2026-09-22424B3SEC
2026-09-22424B3SEC
2026-09-22424B3SEC
2026-09-22424B3SEC
2026-09-226-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-22SEC
2026-09-18424B3SEC
2026-09-18424B3SEC
2026-09-18424B3SEC
2026-09-18424B3SEC
2026-09-186-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-18SEC
2026-09-01424B3SEC
2026-09-01424B3SEC
2026-09-01424B3SEC
2026-09-01424B3SEC
2026-09-016-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-01SEC
2026-08-31424B3SEC
2026-08-31424B3SEC
2026-08-31424B3SEC
2026-08-31424B3SEC
2026-08-316-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-31SEC
2026-08-316-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-31SEC
2026-08-31424B5SEC
2026-08-286-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-28SEC
2026-08-28424B5SEC
2026-08-27424B5SEC
2026-08-27424B3SEC
2026-08-27424B3SEC
2026-08-27424B3SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Boxer Capital Management, LLC4.94%
FLPUTNAM INVESTMENT MANAGEMENT CO3.66%
Bleichroeder LP3.53%
Ikarian Capital, LLC3.50%
Dauntless Investment Group, LLC3.12%
Stonepine Capital Management, LLC3.04%
Point72 Asset Management, L.P.1.77%
UBS Group AG1.49%
Ensign Peak Advisors, Inc0.98%
MILLENNIUM MANAGEMENT LLC0.89%

Funds

Fund% owned
Fidelity Nasdaq Composite Index Fund0.04%
ActivePassive International Equity ETF0.03%
Blackstone Alternative Multi-Strategy Fund0.00%

OakChart. KZIA. Cached 15 minutes.

Some panels did not load: insider.